Literature DB >> 25879306

Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4.

F Montecucco1, V Braunersreuther, F Burger, S Lenglet, G Pelli, F Carbone, R Fraga-Silva, N Stergiopulos, C Monaco, C Mueller, S Pagano, F Dallegri, F Mach, N Vuilleumier.   

Abstract

Auto-antibodies to apolipoprotein A-1 (anti-apoA-1 IgG) were shown to promote inflammation and atherogenesis, possibly through innate immune receptors signalling. Here, we aimed at investigating the role of Toll-like receptors (TLR) 2 and 4 on anti-apoA-1 IgG-induced atherosclerotic plaque vulnerability, myocardial necrosis and mortality in mice. Adult male apolipoprotein E knockout (ApoE)-/- (n=72), TLR2-/-ApoE-/- (n=36) and TLR4-/-Apo-/- (n=28) mice were intravenously injected with 50 µg/mouse of endotoxin-free polyclonal anti-apoA-1 IgG or control isotype IgG (CTL IgG) every two weeks for 16 weeks. Atherosclerotic plaque size and vulnerability were assessed by histology. Myocardial ischaemia and necrosis, respectively, were determined by electrocardiographic (ECG) changes assessed by telemetry and serum troponin I (cTnI) measurements. Impact on survival was assessed by Kaplan-Meier analyses. In ApoE-/- mice, anti-apoA-1 IgG passive immunisation enhanced histological features of atherosclerotic plaque vulnerability (increase in neutrophil and MMP-9 and reduction in collagen content), induced a substantial cTnI elevation (p=0.001), and increased mortality rate by 23 % (LogRank, p=0.04) when compared to CTL IgG. On a subgroup of ApoE-/- mice equipped with telemetry (n=4), a significant ST-segment depression was noted in anti-apoA-1 IgG-treated mice when compared to CTL IgG recipients (p< 0.001), and an acute ST-segment elevation myocardial infarction preceding mouse death was observed in one case. The deleterious effects of anti-apoA-1 IgG on atherosclerotic plaque vulnerability, myocardial necrosis and death were partially reversed in TLR2-/-ApoE-/- and TLR4-/-ApoE-/- backgrounds. In conclusion, anti-apoA-1 auto-antibodies seem to be active mediators of atherosclerotic plaque vulnerability, myocardial necrosis, and mortality in mice through TLR2- and TLR4-mediated pathways.

Entities:  

Keywords:  Antibody; acute myocardial infarction; atherogenesis; mortality

Mesh:

Substances:

Year:  2015        PMID: 25879306     DOI: 10.1160/TH14-12-1039

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

1.  Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events-Brief Report.

Authors:  David Henson; Ayman Samman Tahhan; David Nardo; Arshed Ali Quyyumi; Vincent J Venditto
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-18       Impact factor: 8.311

Review 2.  ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Lab Invest       Date:  2016-05-16       Impact factor: 5.662

Review 3.  Pharmacological Intervention to Modulate HDL: What Do We Target?

Authors:  Nicholas J Woudberg; Sarah Pedretti; Sandrine Lecour; Rainer Schulz; Nicolas Vuilleumier; Richard W James; Miguel A Frias
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

4.  Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms.

Authors:  Panagiotis Antiochos; Pedro Marques-Vidal; Julien Virzi; Sabrina Pagano; Nathalie Satta; Oliver Hartley; Fabrizio Montecucco; François Mach; Zoltán Kutalik; Gerard Waeber; Peter Vollenweider; Nicolas Vuilleumier
Journal:  Front Immunol       Date:  2017-04-18       Impact factor: 7.561

5.  Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes.

Authors:  Nicolas Vuilleumier; Sabrina Pagano; Christophe Combescure; Baris Gencer; Julien Virzi; Lorenz Räber; David Carballo; Sebastian Carballo; David Nanchen; Nicolas Rodondi; Stephan Windecker; Stanley L Hazen; Zeneng Wang; Xinmin S Li; Arnold von Eckardstein; Christian M Matter; Thomas F Lüscher; Roland Klingenberg; Francois Mach
Journal:  J Clin Med       Date:  2019-07-09       Impact factor: 4.241

6.  Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects.

Authors:  Nicolas Vuilleumier; Sabrina Pagano; Fabrizio Montecucco; Alessandra Quercioli; Thomas H Schindler; François Mach; Eleonora Cipollari; Nicoletta Ronda; Elda Favari
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

7.  Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation.

Authors:  Sabrina Pagano; Alessandra Magenta; Marco D'Agostino; Francesco Martino; Francesco Barillà; Nathalie Satta; Miguel A Frias; Annalisa Ronca; François Mach; Baris Gencer; Elda Favari; Nicolas Vuilleumier
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

8.  Does a myocardial infarction boost your (B cell) memory?

Authors:  Claudia Monaco; Jennifer Cole
Journal:  Eur Heart J       Date:  2021-03-01       Impact factor: 29.983

9.  Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion.

Authors:  Alessandra Vecchié; Aldo Bonaventura; Federico Carbone; Davide Maggi; Antonella Ferraiolo; Beatrice Carloni; Gabriella Andraghetti; Laura Affinito Bonabello; Luca Liberale; Vanessa Fetaud; Sabrina Pagano; Franco Dallegri; Renzo Cordera; Fabrizio Montecucco; Nicolas Vuilleumier
Journal:  Biomed Res Int       Date:  2020-03-07       Impact factor: 3.411

10.  Atherosclerotic plaque vulnerability is increased in mouse model of lupus.

Authors:  Marie-Laure Santiago-Raber; Fabrizio Montecucco; Nicolas Vuilleumier; Kapka Miteva; Daniela Baptista; Federico Carbone; Sabrina Pagano; Aline Roth; Fabienne Burger; Francois Mach; Karim J Brandt
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.